Showing posts with label ROI. Show all posts
Showing posts with label ROI. Show all posts

Wednesday, April 24, 2013

“Returns from innovation take a very long time”

Dr. Abhijit Barve, President – R&D, Biocon Ltd. shares how collaborations within the ecosystem can be leveraged to deliver better results

B&E: Could you cite some innovation ecosystem challenges which Biocon particularly faced during various drug discovery processes?
Dr. Abhijit Barve (AB):
Biocon has a state of the art R&D centre, but yet we have faced challenges of not having every sophisticated instrument available that may be required for certain research experiments. In such cases, we have drawn from the external ecosystem and gone ahead with our quest for innovation & were able to tap into resources that were available in the Bangalore area. We have some world-class institutions in the city and we leveraged their services or partnered with them. For Indian companies like us, leveraging what is available in the country and developing competencies internally would be best. And Kiran has been very serious about forging partnerships with a variety of scientific leaders and institutions in the biotech field to place India on the global biotech map.

B&E: How can the stakeholders work towards building an ecosystem for biotech in India?
AB:
It’s important to understand that the returns from innovation take a very long time. Even for biosimilars or novel molecules, the gestation period from the time you actually conceive an idea to commercial introduction is a long development cycle. It is a high risk and reward proposition requiring the right mindset supported by large investments. So, unless you have a huge risk appetite, you wouldn’t want to play in this area.

In the Indian biopharma and pharma industry, VCs and PEs don’t want to invest much because of many reasons. First, they perhaps don’t understand the field too well. Second, because they prefer investing in industries that offer secured returns with relatively low risks. Thirdly, there are limited investment opportunities in these sectors, so their basket of investments cannot be diversified and derisked across multiple technologies. Some VCs have invested in our domain. When there are a couple of success stories in terms of ROI, others will follow.


Source : IIPM Editorial, 2013.
An Initiative of IIPM, Malay Chaudhuri
 
For More IIPM Info, Visit below mentioned IIPM articles
 

Saturday, October 27, 2012

“Marketing was critical...”

UDAY BALDOTA, VP - INVESTOR RELATIONS, SUN PHARMA

B&E: The pharma industry was hit badly during the slowdown. Sun seemed to have escaped. What was prescribed strategically?

Uday Baldota (UB):
We created sustainable revenues streams, with greater differentiation and speed to market. We also focused on cost leadership through vertical integration. There was also a focus on optimising operational costs and making acquisitions which yielded high ROI… Marketing was critical too!

B&E: But recession always hits profit margins...

UB:
Surprisingly, our margins have actually gone up from 70% in 2005-06 to 80% in 2008-09. So even during recession, our margins have not been affected. This simply means that focus on costs has remained a top priority for us even in good times.


Source : IIPM Editorial, 2012.

For More IIPM Info, Visit below mentioned IIPM articles.

 
IIPM : The B-School with a Human Face

The doctor checks in at #44!

low-priced buyouts, cost control & ensuring sustainable revenues, did the trick for sun pharma. what next? STEVEN PHILIP WARNER answers…

At a time when the Indian pharmaceutical sector, once considered immune to downturns, lies battered, Sun Pharma, during FY2008-09, grew its topline by a remarkable 27.3% y-o-y to clock Rs.42.72 billion, and its bottomlines rose by 22.2% y-o-y to touch Rs.18.17 billion. All this catapulted this pharma giant to the 44th spot on the 2009 B&E Power 100 List, making it the only pharma name to feature in the rankings.

Uday Baldota, VP – Investor Relations, Sun Pharma, tells us, “We created sustainable revenues streams, with greater speed to market. A focus on cost leadership and making acquisitions which yielded high ROI proved to be the right strategies…” Although the strategic combo he gives seems straight out of the consultant’s rule book, critics claim the fact is that Sun Pharma has often appeared to be making seat-of-the-pants decisions in the most critical area of inorganic growth, namely M&As – over the past 14 years, Sun has acquired 14 distressed assets. But there is another side to the story as many of these buyouts have come at “low prices” – as Uday defends – therefore renovating them into profit-churning assets proved less challenging. And if fortune has to favour the brave – at a time when other Indian generic giants are facing the heat and are selling-off their crown jewels – Sun’s acquisitions have actually started bearing fruits, key elements powering its financial vehicle even during a downturn!

At the same time, Sun has always been open to diversifications into the right business lanes. When it laid hands on Dadha Pharma & Milmet Labs, it entered the oncological & opthalmological spaces respectively. And if its $454 million Taro deal comes through (“The deal is still on, with some court decisions awaited,” – Uday), it will get an entry into the dermatological market. Thanks to those cheap buyouts, it’s 2009 now, and Sun’s gross profit margins, which for FY2008-09 stood at an extremely high of 79.9%, have never ever looked better!


Source : IIPM Editorial, 2012.

For More IIPM Info, Visit below mentioned IIPM articles.

 
IIPM : The B-School with a Human Face